Phase II trial of NYX-2925 in painful Diabetic Peripheral Neuropathy
Latest Information Update: 25 Nov 2020
At a glance
- Drugs NYX 2925 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- 12 Nov 2020 According to an Aptinyx media release, the company anticipates reporting data from this study in the first half of 2022.
- 30 Sep 2020 New trial record
- 28 Sep 2020 According to an Aptinyx media release, the company is on track to recommence this study in 4Q 2020.